Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 17/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 16/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 9/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dasb SCHEMBL29380613 | 1.00 | SLC6A4 (1.00) | SLC6A4SLC6A2SLC6A3TDP1 | |
| Dasb SCHEMBL586446 | 1.00 | SLC6A4 (1.00) | SLC6A4SLC6A2SLC6A3TDP1 | |
| Dasb SCHEMBL29689760 | 1.00 | SLC6A4 (1.00) | SLC6A4SLC6A2SLC6A3TDP1 | |
| SCHEMBL32890246 | 0.83 | SLC6A4 (0.70) | SLC6A4SLC6A2SLC6A3TDP1 | |
| SCHEMBL1645160 | 0.81 | SLC6A4 (1.00) | SLC6A4SLC6A2SLC6A3TDP1 | |
| SCHEMBL29993160 | 0.81 | SLC6A4 (1.00) | SLC6A4SLC6A2SLC6A3TDP1 | |
| SCHEMBL30543447 | 0.81 | SLC6A4 (1.00) | SLC6A4SLC6A2SLC6A3TDP1 | |
| SCHEMBL1644204 | 0.81 | SLC6A4 (1.00) | SLC6A4SLC6A2SLC6A3TDP1 | |
| SCHEMBL8533846 | 0.80 | SLC6A4 (1.00) | SLC6A4SLC6A2SLC6A3TDP1 | |
| SCHEMBL12728082 | 0.80 | SLC6A4 (1.00) | SLC6A4SLC6A2SLC6A3TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250379726-A1 | SYSTEM AND METHOD FOR SECURE ELECTRONIC DATA TRANSFER | KNECTIQ INC. (US) | 2025-12-11 | — | — | US | claimed |
| WO-2025226286-A1 | SYSTEMS AND METHODS FOR SIMULTANEOUS IMAGING OF MULTIPLE POSITRON EMISSION TOMOGRAPHY (PET) TRACERS | MULTIF UNCTIONAL IMAGING LLC (US) | 2025-10-30 | — | — | WO | claimed |
| US-20250329024-A1 | SYSTEMS AND METHODS FOR SIMULTANEOUS IMAGING OF MULTIPLE POSITRON EMISSION TOMOGRAPHY (PET) TRACERS | MultiFunctional Imaging LLC (US) | 2025-10-23 | — | — | US | claimed |
| US-20240299598-A1 | METHODS FOR DETECTING CCR2 RECEPTORS | WASHINGTON UNIVERSITY (US) | 2024-09-12 | — | — | US | claimed |
| US-12016935-B2 | Methods for detecting CCR2 receptors | WASHINGTON UNIVERSITY (US) | 2024-06-25 | — | — | US | claimed |
| WO-2023111960-A1 | METHOD AND PORTABLE DEVICE FOR MONITORING AND IDENTIFYING CARDIAC EVENTS | SMART HEALTH SOLUTIONS S.A.P.I. DE C.V. (MX) | 2023-06-22 | — | — | WO | claimed |
| EP-4727538-A2 | NEW FORMULATIONS FOR MENTAL DISORDERS OR MENTAL ENHANCEMENT | Tactogen Inc. (US) | 2026-04-22 | — | — | EP | disclosed |
| US-20260102372-A1 | NEW FORMULATIONS FOR MENTAL DISORDERS OR MENTAL ENHANCEMENT | TACTOGEN INC (US) | 2026-04-16 | — | — | US | disclosed |
| EP-4708772-A2 | SYSTEM AND METHOD FOR SECURE ELECTRONIC DATA TRANSFER | Knectiq Inc. (US) | 2026-03-11 | — | — | EP | disclosed |
| US-12514937-B2 | Methods for detecting CCR2 receptors | WASHINGTON UNIVERSITY (US) | 2026-01-06 | — | — | US | disclosed |
| US-20250379726-A1 | SYSTEM AND METHOD FOR SECURE ELECTRONIC DATA TRANSFER | KNECTIQ INC. (US) | 2025-12-11 | — | — | US | disclosed |
| WO-2025226286-A1 | SYSTEMS AND METHODS FOR SIMULTANEOUS IMAGING OF MULTIPLE POSITRON EMISSION TOMOGRAPHY (PET) TRACERS | MULTIF UNCTIONAL IMAGING LLC (US) | 2025-10-30 | — | — | WO | disclosed |
| EP-3918749-B1 | SYSTEM AND METHOD FOR SECURE ELECTRONIC DATA TRANSFER | KNECTIQ INC (US) | 2025-10-29 | — | — | EP | disclosed |
| US-11345123-B2 | Monolithic integration of hybrid perovskite single crystals with silicon for highly sensitive x-ray detectors | THE BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) | 2022-05-31 | — | — | US | disclosed |
| CN-114539243-A | Novel deuterium-substituted Positron Emission Tomography (PET) imaging agents and their pharmacological use | 五一一制药股份有限公司 | 2022-05-27 | — | — | CN | disclosed |
| US-20220118118-A1 | BENZAZEPIN-L,7-DIOL-DERIVED RADIOLABELED LIGANDS WITH HIGH IN VIVO NMDA SPECIFICITY | ETH ZURICH (CH) | 2022-04-21 | — | — | US | disclosed |
| WO-2022076523-A1 | METHODS AND COMPOSITIONS FOR IMAGING AND TREATING CANCER | WASHINGTON UNIVERSITY (US) | 2022-04-14 | — | — | WO | disclosed |
| CN-113395067-B | Logic gate circuit based on MOS tube stacking extension structure | 宁波大学科学技术学院 | 2022-04-08 | — | — | CN | disclosed |
| CN-113328741-B | P-type semi-stacked sub-threshold standard unit based on Schmitt trigger circuit | 宁波大学科学技术学院 | 2022-03-29 | — | — | CN | disclosed |
| US-20220060321-A1 | SYSTEM AND METHOD FOR SECURE ELECTRONIC DATA TRANSFER | KNECTIQ INC. (US) | 2022-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12016935-B2 | Methods for detecting CCR2 receptors | CCR2, CCR1, CCR5 | SLC6A4 2794/4885SLC6A2 2122/4885SLC6A3 2052/4885 |
| US-20260102372-A1 | NEW FORMULATIONS FOR MENTAL DISORDERS OR MENTAL ENHANCEMENT | SLC6A4, SLC6A2, SLC6A3 | SLC6A4 1/4885SLC6A2 2/4885SLC6A3 3/4885 |
| US-20220118118-A1 | BENZAZEPIN-L,7-DIOL-DERIVED RADIOLABELED LIGANDS WITH HIGH IN VIVO NMDA SPECIFICITY | GRIN1, GRIN2D, GRIN3B | SLC6A4 161/4885SLC6A2 185/4885SLC6A3 114/4885 |
| US-20240299598-A1 | METHODS FOR DETECTING CCR2 RECEPTORS | CCR2, CCR1, CCR5 | SLC6A4 2794/4885SLC6A2 2122/4885SLC6A3 2052/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.